ArticleCancers2023

Peak Risk of Recurrence Occurs during the First Two Years after a Pancreatectomy in Patients Receiving Neoadjuvant FOLFIRINOX.

Marie-Sophie Alfano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.